Copper

• Phase 3 drilling at NGEx Minerals' Lunahuasi project has significantly expanded the deposit dimensions to 1.2km north-south, 1.7km east-west, and 1.2km vertically, with mineralization remaining open in all directions. • Exceptional gold grades comparable to world-class gold-only deposits were encountered, including intersections of 27.4m at 23.17 g/t Au and 8.2m at 39.11 g/t Au, suggesting gold could become a significant part of the project's value proposition. • The company has improved its geological understanding of the deposit, identifying that high-grade vein mineralization correlates with northeast trending, steeply dipping structural corridors, which will guide future exploration efforts.

• Monopar Therapeutics presented late-breaker data at EASL 2025 showing sustained clinical improvements in Wilson disease patients treated with ALXN1840 (tiomolybdate choline) over a median treatment duration of 2.63 years. • The pooled analysis from multiple clinical trials (n=255) demonstrated improvements in patient-reported symptoms, copper mobilization, and clinical assessments, with fewer than 5% of patients experiencing drug-related serious adverse events. • Patients reported higher convenience and effectiveness with ALXN1840 compared to standard of care, suggesting the drug candidate could provide meaningful benefits for the management of this rare genetic condition.

Fortress Biotech secured FDA approvals for two key products in Q4 2024: Emrosi for inflammatory lesions of rosacea and UNLOXCYT for advanced cutaneous squamous cell carcinoma, with commercial launch of Emrosi already underway.

• Phase I drilling at Chile's Mostaza Mine has yielded exceptional copper-silver assay results, with hole CNG25 DD001 returning 20m @ 3.31% Cu and 270g/t Ag from 27m depth, demonstrating high-grade mineralization continuity. • Great Southern Copper has mobilized two diamond drill rigs for Phase II drilling, targeting depth and strike extensions of the high-grade Cu-Ag mineralization while also exploring structural trends to the south. • The company aims to expand on historically reported resources with 1,000-1,500m of planned drilling, with results contributing to forthcoming metallurgical and geotechnical studies as GSC progresses toward demonstrating economic viability.

• Orphalan has launched trientine tetrahydrochloride ("Ke Pei Ou") in China through a strategic partnership with SPH Kyuan Trade, becoming the first European company to introduce an orphan drug for Wilson disease in this market. • The treatment addresses a critical unmet need for Chinese Wilson disease patients who cannot tolerate penicillamine, the previous standard therapy, offering an alternative that is already available in over 20 countries globally. • Orphalan has established a local entity in Shanghai led by Grace Li as General Manager, demonstrating its commitment to ensuring Chinese patients and healthcare providers have access to advanced Wilson disease treatment options.